OpGen Inc. (OPGN)

Our attorneys are investigating customer losses in OpGen Inc., an investment offered and sold by National Securities Corporation Inc. (NSC) and Northland Securities to its retail clients.

If you have suffered losses in OpGen Inc., please contact our lawyers for a free and confidential consultation concerning your legal rights and the possibility of recovery.

At Silver Law Group, we know from experience that not every investment recommended and solicited by a stockbroker is suitable and appropriate for the customer. We have seen, particularly in the initial public offering (IPO) space, that investors are often falsely promised high returns and low risk, when in truth the investment is speculative and subject to the loss of principal. Your financial advisor and the securities firm who sells the investment have a legal duty to fully explain the nature of the investment, its inherent risks and the possibility of loss.

Brokers and financial advisors may push risky initial public offerings on unsuspecting investors based upon strong financial incentives, including large commission payouts. Investors in such offerings must realize that these investments are inherently risky and should be considered very carefully before making a decision to invest. Representations made by stockbrokers that such investments are “safe” and “guaranteed” are typically false and are a red flag of possible fraud.

In 2015, National Securities Corporation underwrote OpGen Inc.’s stock offering. At the close of the offering, National Securities Corporation raised over 17 million ($17,100,000.00). OpGen Inc. was listed on the Nasdaq under the stock symbol “OPGN” with an initial offering price of $5.27 per share. As of November 13, 2017, OpGen Inc stock is worth $0.27 per share.

OpGen, Inc. states on their website that they are harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. They say their products and services are designed to enable the rapid identification of hospital patients who are colonized or infected with life-threatening, multi-drug resistant organisms, MDROs.

Silver Law Group represents investment fraud victims in cases to recover their investment losses. If you have questions about your legal rights, please contact Scott Silver of the Silver Law Group for a free consultation at ssilver@silverlaw.com or toll-free at (800) 975-4345.